“Cold” tumor–bearing patients may benefit from the addition of drugs aimed to increase antigen load, such as chemotherapy, radiotherapy, epigenetic modulators, or STING agonists (43), whereas targeting immunosuppressive cells could be a valid therapeutic strategy for T cell excluded tumors. This evidence concerns the gene STING1 and neoplasm.